MARKET

JSPRW

JSPRW

Jasper Therapeutics Inc
NASDAQ
0.1000
-0.0150
-13.04%
Opening 09:51 12/22 EST
OPEN
0.1000
PREV CLOSE
0.1150
HIGH
0.1000
LOW
0.1000
VOLUME
2.84K
TURNOVER
--
52 WEEK HIGH
0.2300
52 WEEK LOW
0.0375
MARKET CAP
--
P/E (TTM)
-0.0169
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPRW last week (1215-1219)?
Weekly Report · 9h ago
Weekly Report: what happened at JSPRW last week (1208-1212)?
Weekly Report · 12/15 09:31
Weekly Report: what happened at JSPRW last week (1201-1205)?
Weekly Report · 12/08 09:30
BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise
Reuters · 12/02 12:17
Jasper Therapeutics Reports Positive Preliminary Data from Briquilimab Asthma Study and Completes BEACON Investigation
Reuters · 12/02 12:00
JASPER THERAPEUTICS REPORTS POSITIVE PRELIMINARY DATA FROM ETESIAN STUDY OF BRIQUILIMAB IN ASTHMA AND FINDINGS FROM BEACON STUDY INTERNAL INVESTIGATION
Reuters · 12/02 12:00
JASPER THERAPEUTICS INC: BRIQUILIMAB WAS WELL TOLERATED IN STUDY, DEMONSTRATING A FAVORABLE SAFETY PROFILE
Reuters · 12/02 12:00
Jasper Therapeutics to Present Preliminary Asthma and Urticaria Study Data in Investor Webinar
Reuters · 12/01 21:30
More
About JSPRW
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPRW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPRW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPRW stock methods without spending real money on the virtual paper trading platform.